In this regard, it has been demonstrated that GPER agonists upregulate the expression of genes associated with tumor progression like c-fos (93–96), cyclins A, D1, and E (97, 98), the connective tissue growth factor (CTGF) (99), and the early growth response-1 (Egr-1) (100). This evidence concerns the gene CCN2 and neoplasm.